小智港股覆盤 | 5月10日
今日，港股三大指數集體下跌。截止收盤，恆生指數跌1.84%，報19633點。國企指數大跌2.22%，報6658點。恆生科技指數大跌3.22%，報3906點。市場約488只個股上漲，1213只個股下跌。成交額突破1436.8億港幣，和昨天同期相比增長21.94%。南下資金淨流入64.29億港幣。
盤面上，食品零售板塊活躍。佳華百貨控股漲超18%；克莉絲汀漲超10%；COOL LINK漲超4%；高鑫零售漲超3%；萬隆控股集團漲超1%。
機械製造板塊活躍。盛力達科技漲超17%；大唐西市漲超7%；迪諾斯環保漲超6%；創科實業漲超5%；鐵建裝備漲超2%。
休閒用品板塊活躍。好孩子國際漲超6%；CMON漲超4%；美力時集團、彩星玩具等多股漲超2%；中國口腔產業漲超1%。
汽車板塊暴跌。蔚來-SW跌超10%；小鵬汽車-W跌超9%；理想汽車-W跌超6%；比亞迪股份、長城汽車等多股跌超5%。蔚來中高端品牌生產基地選址合肥，計劃2024年投產；招商證券(香港)：維持理想汽車-W“買入”評級，目標價159港元；比亞迪股份低開逾9%，據報長沙比亞迪部分產線停產整頓；長城汽車：4月共有7.4萬元“長汽轉債”已轉換成公司股票。
信息技術板塊全線走低。萬國數據-SW跌超10%；南大蘇富特、MINDTELL TECH等多股跌超9%；倢冠控股跌超7%；索信達控股跌超6%。萬國數據-SW擬5月18日召開董事會會議，審批一季度業績；索信達控股5月4日於股份獎勵計劃下發行合計117.46萬股。
生物科技板塊暴跌。三葉草生物-B跌超22%；再鼎醫藥SB-新跌超19%；百濟神州跌超10%；開拓藥業-B、康寧傑瑞製藥-B等多股跌超6%。百濟神州首季產品收入增長146%至2.616億美元，研發費用爲3.899億美元；開拓藥業ALK-1單抗聯合療法二期試驗完成美國首例患者給藥。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
